Baduanjin Intervention in Clinical Studies After Coronary Revascularization Surgery
19. Mai 2026 aktualisiert von: Liu Qiang
- To evaluate the efficacy and safety of the Baduanjin exercise programme in patients following coronary revascularisation surgery;
- To develop a traditional Chinese medicine (TCM) rehabilitation protocol and evaluation system for patients following coronary revascularisation surgery;
- To clarify the advantages of TCM rehabilitation in the post-operative management of coronary revascularisation surgery and to provide high-level evidence-based medical evidence for TCM rehabilitation protocols.
Studienübersicht
Status
Noch keine Rekrutierung
Detaillierte Beschreibung
Patients who had undergone coronary revascularisation were selected as study subjects and divided into an intervention group (standard Western medical treatment + Baduanjin) and a control group (standard Western medical treatment + aerobic exercise). The intervention lasted 12 weeks, with follow-up assessments conducted at baseline (on the day of enrolment), 6 weeks, 12 weeks, 24 weeks, 36 weeks and 48 weeks. The incidence of major adverse cardiovascular events was used as the primary efficacy endpoint, secondary efficacy endpoints included Traditional Chinese Medicine syndrome scores, echocardiography, Holter monitoring, the Minnesota Quality of Life Questionnaire, cardiac enzymes, blood lipids and blood glucose; safety endpoints comprised vital signs, complete blood count, liver and kidney function, and other adverse reactions and events.
Translated with DeepL.com (free version)
Studientyp
Interventionell
Einschreibung (Geschätzt)
310
Phase
- Unzutreffend
Kontakte und Standorte
Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.
Studienkontakt
- Name: Liu Qiang, PhD
- Telefonnummer: +86 13588121905
- E-Mail: 19981011@zcmu.edu.cn
Teilnahmekriterien
Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.
Zulassungskriterien
Studienberechtigtes Alter
- Erwachsene
- Älterer Erwachsener
Akzeptiert gesunde Freiwillige
Nein
Beschreibung
Inclusion Criteria:
- Participants who meet the diagnostic criteria for coronary heart disease
- Participants who underwent successful percutaneous coronary intervention
- Participants aged between 18 and 80
- Participants of any gender
- Participants who have signed an informed consent form
Exclusion Criteria:
- Subjects with severe hepatic or renal impairment
- subjects with severe electrolyte disturbances
- subjects with severe haematological disorders or malignant tumours
- pregnant or breastfeeding women
- subjects with psychiatric disorders
- subjects with cognitive impairment (e.g. dementia, post-stroke cognitive impairment) that prevents them from understanding or carrying out exercise instructions
- Subjects scheduled to undergo repeat revascularisation surgery in the near future
- Subjects with other severe cardiovascular diseases such as uncontrolled hypertension, angina pectoris, rapid arrhythmias, high-degree or complete atrioventricular block (without a pacemaker), acute severe aortic stenosis, decompensated heart failure (NYHA Class IV), deep vein thrombosis, obstructive hypertrophic cardiomyopathy, acute pericarditis or myocarditis, acute endocarditis, or acute aortic dissection
- Participants with acute pulmonary embolism or chronic lung disease accompanied by symptoms of dyspnoea (occurring at rest or with minimal exertion)
- Subjects with impaired limb mobility or who are unable to move independently;
- Subjects with Shy-Drager syndrome
- Subjects who have participated in a clinical trial involving other drugs or exercise interventions within the past month
- Subjects deemed by the investigator to have other conditions rendering them unsuitable for participation in the trial
Studienplan
Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Single
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: Experimental Group
Standardized Western medical treatment + Standardized Baduanjin rehabilitation training.
Standardised Baduanjin training was conducted under the supervision of a qualified doctor or physiotherapist.
Participants trained four times a week, performing the routine twice at each session.
Progress was monitored and guidance provided through the creation of a WeChat group and the distribution of video materials.
Participants received weekly guidance, either online or in person, and uploaded videos of their training sessions.
Throughout the study, all sessions were regularly monitored and feedback was provided to ensure correct instruction.
|
Standardised Baduanjin training was conducted under the supervision of a qualified doctor or physiotherapist.
Participants trained four times a week, performing the routine twice at each session.
Progress was monitored and guidance provided through the creation of a WeChat group and the distribution of video materials.
Participants received weekly guidance, either online or in person, and uploaded videos of their training sessions.
Throughout the study, all sessions were regularly monitored and feedback was provided to ensure correct instruction.
|
|
Aktiver Komparator: Control Group
Standardized Western medical treatment + Aerobic exercise training.
Aerobic exercise training included climbing stairs, jogging, brisk walking and cycling.
The exercise intensity for the aerobic exercise group was monitored, with maximum heart rate estimated as 208 minus (0.7 × age).
Participants received weekly guidance, either online or in person, and uploaded videos of their training sessions.
Throughout the study, all sessions were regularly monitored and feedback was provided to ensure correct guidance.
|
Aerobic exercise training included climbing stairs, jogging, brisk walking and cycling.
The exercise intensity for the aerobic exercise group was monitored, with maximum heart rate estimated as 208 minus (0.7 × age).
Participants received weekly guidance, either online or in person, and uploaded videos of their training sessions.
Throughout the study, all sessions were regularly monitored and feedback was provided to ensure correct guidance.
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Incidence of major cardiovascular adverse events
Zeitfenster: From enrolment to 48 weeks of follow-up
|
Using medical record forms and clinical diagnostic criteria, assess the number of cases of the following cardiovascular adverse events: all-cause mortality, subacute in-stent thrombosis, perioperative myocardial infarction, recurrent myocardial infarction, recurrent unstable angina, repeat revascularisation, and readmission for angina or heart failure; and record the date of occurrence, basis for diagnosis, management measures, outcome (recovery/persistence/worsening/death), causality (definitely related/probably related/probably unrelated/definitely unrelated/cannot be determined) and the impact on the study (whether the patient withdrew or the study was unblinded).
Units: cases or categorical variables.
|
From enrolment to 48 weeks of follow-up
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
TCM Syndrome Score
Zeitfenster: From enrolment to 48 weeks of follow-up
|
Using the 'Scoring Table for Syndromes in Traditional Chinese Medicine', the following symptoms were assessed: chest pain, chest tightness, palpitations, shortness of breath, exacerbation on exposure to cold, mental fatigue and physical weakness, spontaneous sweating, reluctance to speak, obesity, epigastric fullness and loss of appetite, gooseflesh, a dark purple complexion or lips, a sensation of heaviness in the head as if wrapped in a cloth, coughing up phlegm or wheezing in the throat, aversion to cold and cold limbs, hot flushes and night sweats, dry mouth and throat, pale conjunctiva of the eyelids, severe bitter taste in the mouth, and emotional depression or frequent sighing.
These 20 symptoms were each scored on a scale of 0-3 (0 = absent, 1 = mild, 2 = moderate, 3 = severe); simultaneously record bowel movements and urination, tongue quality, tongue shape, tongue coating, sublingual veins, pulse characteristics, and the qualitative classification of primary syndromes.
|
From enrolment to 48 weeks of follow-up
|
|
Echocardiogram
Zeitfenster: Enrollment and 12-week follow-up
|
This study used echocardiography (ultrasound diagnostic equipment) to assess the following parameters: left ventricular ejection fraction (LVEF, %); left ventricular short-axis fraction of shortening (FS, %); left ventricular end-diastolic diameter (LVEDD, unit: mm), left ventricular end-systolic diameter (LVESD, unit: mm), left ventricular posterior wall thickness (LVPW, unit: mm), and interventricular septal thickness (IVS, unit: mm); simultaneously assess the following left ventricular diastolic function parameters: E/A ratio (unit: none, i.e. ratio) and mean E/e' ratio (unit: none) ; and record the overall assessment and conclusions, including major findings such as segmental wall motion abnormalities and reduced left ventricular diastolic function (qualitative description), as well as comparisons with previous examinations (newly developed/improved compared to previous findings/worsened compared to previous findings/no change/no comparable data available).
|
Enrollment and 12-week follow-up
|
|
Dynamic Electrocardiogram
Zeitfenster: Enrollment and 12-week follow-up
|
This study assessed the following parameters using 24-hour Holter monitoring: mean, maximum and minimum heart rates and durations; total number of atrial premature beats (P' wave morphology), number of atrial tachycardia episodes, duration of atrial fibrillation/flutter (P wave replaced by f/F waves); total number of ventricular premature beats (QRS complex width ≥120 ms, without preceding P wave), number of paired ventricular premature beats and ventricular tachycardia episodes; longest RR interval and asystole/conduction block; amplitude and duration of ST-segment depression events (measured 80 ms after the J point); heart rate variability (SDNN); and P-wave width, PR interval, QRS width, QT interval and QTc interval (Bazett formula) measured during sinus rhythm.
|
Enrollment and 12-week follow-up
|
|
Minnesota Quality of Life Scale
Zeitfenster: From enrolment to 48 weeks of follow-up
|
The standardised Minnesota Heart Failure Quality of Life Questionnaire was completed by the patients themselves or with the assistance of the investigators to quantitatively assess their quality of life.
The Minnesota Health-Related Quality of Life Questionnaire (MLHFQ) is a standardised tool used to quantify the overall impact of heart failure on patients' physical, emotional and social functioning.
The total score ranges from 0 to 105; a higher score indicates poorer quality of life, whilst a lower score indicates better health-related quality of life.
A total score below 24 is considered an indicator of good quality of life.
|
From enrolment to 48 weeks of follow-up
|
|
Cardiac enzymes
Zeitfenster: Enrollment and 12-week follow-up
|
Peripheral venous blood samples were collected from patients at each follow-up visit and analysed biochemically by the central laboratory to record levels of cardiac enzymes, including creatine kinase isoenzymes.
|
Enrollment and 12-week follow-up
|
|
blood lipids
Zeitfenster: Enrollment and 12-week follow-up
|
Blood samples were collected from patients' peripheral veins at each visit and sent to the central laboratory for biochemical analysis to determine levels of four lipid parameters, including total cholesterol.
|
Enrollment and 12-week follow-up
|
|
Fasting blood glucose
Zeitfenster: Enrollment and 12-week follow-up
|
Peripheral venous blood samples were collected from patients at each visit, and biochemical analyses were carried out by the central laboratory, with the results recorded.
|
Enrollment and 12-week follow-up
|
|
Peripheral venous blood samples were collected from patients at each visit, and biochemical analyses were carried out by the central laboratory, with the results recorded.
Zeitfenster: Enrollment and 12-week follow-up
|
Peripheral venous blood samples were collected from patients at each visit, and biochemical analyses were carried out by the central laboratory, with the results recorded.
|
Enrollment and 12-week follow-up
|
Andere Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Red blood cell count
Zeitfenster: Enrollment and 12-week follow-up
|
As part of the objective assessment, blood samples were taken for a complete blood count at the time points specified in the study.
|
Enrollment and 12-week follow-up
|
|
Haemoglobin concentration
Zeitfenster: Enrollment and 12-week follow-up
|
Fasting blood glucose and haemoglobin A1c levels were recorded by collecting peripheral venous blood samples from patients at each visit and having them analysed by the central laboratory.
|
Enrollment and 12-week follow-up
|
|
White blood cell count
Zeitfenster: Enrollment and 12-week follow-up
|
Fasting blood glucose and haemoglobin A1c levels were recorded by collecting peripheral venous blood samples from patients at each visit and having them analysed by the central laboratory.
|
Enrollment and 12-week follow-up
|
|
Platelet count
Zeitfenster: Enrollment and 12-week follow-up
|
Fasting blood glucose and haemoglobin A1c levels were recorded by collecting peripheral venous blood samples from patients at each visit and having them analysed by the central laboratory.
|
Enrollment and 12-week follow-up
|
|
Haematocrit
Zeitfenster: Enrollment and 12-week follow-up
|
Fasting blood glucose and haemoglobin A1c levels were recorded by collecting peripheral venous blood samples from patients at each visit and having them analysed by the central laboratory.
|
Enrollment and 12-week follow-up
|
|
Alanine transaminase
Zeitfenster: Enrollment and 12-week follow-up
|
As part of the objective assessment, blood samples were taken at the time points specified in the study to test liver and kidney function markers.
|
Enrollment and 12-week follow-up
|
|
Aspartate transaminase
Zeitfenster: Enrollment and 12-week follow-up
|
As part of the objective assessment, blood samples were taken at the time points specified in the study to test liver and kidney function markers.
|
Enrollment and 12-week follow-up
|
|
Alkaline phosphatase
Zeitfenster: Enrollment and 12-week follow-up
|
As part of the objective assessment, blood samples were taken at the time points specified in the study to test liver and kidney function markers.
|
Enrollment and 12-week follow-up
|
|
Potassium
Zeitfenster: Enrollment and 12-week follow-up
|
As part of the objective assessment, blood samples were taken at the time points specified in the study to test liver and kidney function markers.
|
Enrollment and 12-week follow-up
|
|
Sodium
Zeitfenster: Enrollment and 12-week follow-up
|
As part of the objective assessment, blood samples were taken at the time points specified in the study to test liver and kidney function markers.
|
Enrollment and 12-week follow-up
|
|
Total bilirubin
Zeitfenster: Enrollment and 12-week follow-up
|
As part of the objective assessment, blood samples were taken at the time points specified in the study to test liver and kidney function markers.
|
Enrollment and 12-week follow-up
|
|
Blood urea nitrogen
Zeitfenster: Enrollment and 12-week follow-up
|
As part of the objective assessment, blood samples were taken at the time points specified in the study to test liver and kidney function markers.
|
Enrollment and 12-week follow-up
|
|
Creatinine
Zeitfenster: Enrollment and 12-week follow-up
|
As part of the objective assessment, blood samples were taken at the time points specified in the study to test liver and kidney function markers.
|
Enrollment and 12-week follow-up
|
|
Uric acid
Zeitfenster: Enrollment and 12-week follow-up
|
As part of the objective assessment, blood samples were taken at the time points specified in the study to test liver and kidney function markers.
|
Enrollment and 12-week follow-up
|
|
Homocysteine
Zeitfenster: Enrollment and 12-week follow-up
|
As part of the objective assessment, blood samples were taken at the time points specified in the study to test liver and kidney function markers.
|
Enrollment and 12-week follow-up
|
Mitarbeiter und Ermittler
Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.
Studienaufzeichnungsdaten
Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.
Haupttermine studieren
Studienbeginn (Geschätzt)
1. Juli 2026
Primärer Abschluss (Geschätzt)
30. Juni 2028
Studienabschluss (Geschätzt)
31. Dezember 2028
Studienanmeldedaten
Zuerst eingereicht
12. Mai 2026
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
19. Mai 2026
Zuerst gepostet (Tatsächlich)
27. Mai 2026
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
27. Mai 2026
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
19. Mai 2026
Zuletzt verifiziert
1. Mai 2026
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- ZSLL-KY-2026-026-01
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
NEIN
Beschreibung des IPD-Plans
Firstly, the informed consent forms obtained from participants prior to the commencement of the study did not include any provisions authorising the open sharing of de-identified individual data on public platforms.
Out of strict respect for participants' right to privacy and the scope of their informed consent, it is not appropriate to make the data publicly available.
Secondly, as this study involves multi-centre collaboration, the ownership of data and the mechanisms for data sharing across the various sub-centres have not yet been uniformly clarified in the collaboration agreement.
Furthermore, the individualised data collected in this trial-such as Traditional Chinese Medicine (TCM) syndrome scores and tongue and pulse characteristics-lacks recognised public data-sharing standards for its de-identification and standardisation.
Direct disclosure could lead to the data being misinterpreted or misused.
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Nein
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Nein
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .